Coronavirus | Featured Stories

COVID Breakthrough: New Pfizer anti-viral pill

Pfizer
In this photo taken Wednesday, May 19, 2010, a sign in front of the Pfizer research and manufacturing facility in Pearl River, N.Y. Pfizer announced Tuesday that it would layoff 1250 people at the plant by 2014. The company will retain one research division at the site, employing 1,000. (AP Photo/Mark Lennihan)

Following Pfizer’s worldwide rollout of its COVID vaccine, Friday morning, another potential breakthrough in the fight against the virus…and anti-viral pill.
Pfizer saying early trial results of its anti-viral COVID pill show it reduced the risk of hospitalization or death by 89%.
The pill, still known by its experimental name PF-07321332, is what’s known as a protease inhibitor. It’s designed to stop the virus from multiplying. Giving it along with ritonavir slows its breakdown in the body, the company said.


More than 1200 people included in the study were considered high-risk and started taking the pills within 3 days of developing COVID symptoms.
The drug is now on track for potential authorization in early 2022 which is not far behind another antiviral COVID pill developed by Merck.